$heff's $tation of $tocks & $olid DD

[$heff]

w/ PARD ($2.50) Abstract Conclusions: Neurotoxicity with FOLPI was less frequent and less severe compared to FOLFOX. Hematologic toxicity with FOLPI was manageable. FOLPI treatment of first-line CRC had similar disease control and survival rates to FOLFOX supporting picoplatin as a potential neuropathy-sparing alternative to the use of oxaliplatin.


The market is large for Colorectal Cancer. FOLPI is looking to replace FOLFOX (5fu/leucovorin + Oxaliplatin) in 1st line Colorectal Cancer. Oxaliplatin is a billion dollar chemotherapy w/ colorectal cancer being the real winner for PARD.